Efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: A systematic review for the EAACI biologicals guidelines.

Allergy
Ioana AgacheMarek Jutel

Abstract

This systematic review evaluates the efficacy, safety and economic impact of dupilumab compared to standard of care for uncontrolled moderate-to-severe atopic dermatitis (AD). Pubmed, EMBASE and Cochrane Library were searched for RCTs and health economic evaluations. Critical and important AD-related outcomes were considered. The risk of bias and the certainty of the evidence were assessed using GRADE. Seven RCTs including 1845 subjects >12 years treated with dupilumab 16 to 52 weeks were evaluated. For adults, there is high certainty that dupilumab decreases SCORAD (MD -30,72; 95% CI -34,65% to -26,79%) and EASI-75 (RR 3.09; 95% CI 2.45 to 3.89), pruritus (RR 2.96; 95% CI 2.37 to 3.70), rescue medication (RR 3.46; 95% CI 2.79 to 4.30), sleep disturbance (MD -7.29; 95% CI -8.23 to -6.35) and anxiety/depression (MD -3.08; 95% CI -4.41 to -1.75) and improves quality of life (MD -4.80; 95% CI -5.55 to -4.06). The efficacy for adolescents is similar. Dupilumab-related adverse events (AEs) slightly increase (low certainty). The evidence for dupilumab-related serious AE is uncertain. The incremental cost-effectiveness ratio ranged from 28 500 £ (low certainty) to 124 541 US$ (moderate certainty). More data on long-term safety are nee...Continue Reading

References

Jan 1, 1997·Dermatology : International Journal for Clinical and Investigative Dermatology·B KunzA Taïeb
Feb 8, 2002·Journal of Psychosomatic Research·Ingvar BjellandDag Neckelmann
Apr 26, 2008·BMJ : British Medical Journal·Gordon H GuyattUNKNOWN GRADE Working Group
Jul 12, 2008·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·John NixonGerard de Pouvourville
Nov 28, 2008·BMC Medical Research Methodology·Gerta RückerMartin Schumacher
Aug 12, 2009·PharmacoEconomics·Florencia Hutter, Fernando Antoñanzas
Aug 2, 2011·Journal of Clinical Epidemiology·Gordon H GuyattUNKNOWN GRADE Working Group
Aug 2, 2011·Journal of Clinical Epidemiology·Gordon H GuyattHolger J Schünemann
Oct 20, 2011·BMJ : British Medical Journal·Julian P T HigginsUNKNOWN Cochrane Statistical Methods Group
Aug 28, 2014·The New England Journal of Medicine·Peter J NeumannMilton C Weinstein
Jan 24, 2015·Dermatology : International Journal for Clinical and Investigative Dermatology·M K A BasraA Y Finlay
Jun 11, 2016·Allergology International : Official Journal of the Japanese Society of Allergology·Ioana Agache, Cezmi A Akdis
Aug 9, 2016·The Journal of Allergy and Clinical Immunology·Thomas WerfelCezmi A Akdis
Oct 4, 2016·The New England Journal of Medicine·Eric L SimpsonUNKNOWN SOLO 1 and SOLO 2 Investigators
Feb 17, 2017·The Cochrane Database of Systematic Reviews·Andreas LundhLisa Bero
Aug 2, 2017·Research Synthesis Methods·Gerta RückerGuido Schwarzer
Sep 22, 2017·Dermatology and Therapy·Andreas KuznikSean D Sullivan
Nov 4, 2017·American Journal of Clinical Dermatology·Igor SnastYael Anne Leshem
Nov 29, 2017·International Immunopharmacology·Zuzhen OuWeikang Zhou
Dec 24, 2017·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·Peck Y Ong
Feb 24, 2018·Journal of Dermatological Science·Fa-Ping WangFeng-Ming Luo
Nov 11, 2018·The Journal of Allergy and Clinical Immunology·Kilian EyerichNick J Reynolds
Aug 21, 2019·The Journal of Allergy and Clinical Immunology. in Practice·Alexandra LeonardMichael D Howell
Aug 25, 2019·Allergy·Stefanie EyerichKilian Eyerich
Nov 2, 2019·Journal of the American Academy of Dermatology·Ana B PavelEmma Guttman-Yassky
Nov 13, 2019·Journal of Clinical Epidemiology·Nancy SantessoUNKNOWN GRADE Working Group
Feb 28, 2020·Science Translational Medicine·Graham Ogg
Apr 23, 2020·Allergy·Cezmi A AkdisOscar Palomares
Jun 9, 2020·The Journal of Allergy and Clinical Immunology·Zeynep Celebi SözenerCezmi A Akdis

❮ Previous
Next ❯

Citations

Dec 15, 2020·Dermatology and Therapy·Firas Constantin KreeshanHamish John Alexander Hunter
Mar 10, 2021·The Journal of Allergy and Clinical Immunology. in Practice·Thanaporn RatchataswanWanda Phipatanakul
Apr 9, 2021·The British Journal of Dermatology·B ChrétienE Ezine
Jun 12, 2021·Expert Opinion on Drug Safety·Wojciech FrancuzikMargitta Worm
Jun 30, 2021·Anales De Pediatría·Mercedes Escarrer-JaumeMontserrat Álvaro-Lozano
Jun 14, 2021·Anales de pediatría : publicación oficial de la Asociación Española de Pediatría (A.E.P.)·Mercedes Escarrer-JaumeMontserrat Álvaro-Lozano
Aug 23, 2021·Contact Dermatitis·Yasutaka MitamuraCezmi A Akdis
Sep 15, 2021·Allergy·Ismail OgulurCezmi A Akdis

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atopic Dermatitis

Atopic dermatitis is a chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. Discover the latest research on atopic dermatitis here.